DESCRIPTION OF A RECEPTOR FOR P24 ON THE CELL SURFACE OF INTERLEUKIN-2 ACTIVATED LYMPHOCYTES (MEETING ABSTRACT) NLM AIDSLINE Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


DESCRIPTION OF A RECEPTOR FOR P24 ON THE CELL SURFACE OF INTERLEUKIN-2 ACTIVATED LYMPHOCYTES (MEETING ABSTRACT)

Proc Annu Meet Am Assoc Cancer Res; 32:A1677 1991. Unique Identifier : AIDSLINE ICDB/91674478
Stine K; Tulane Univ. Sch. of Medicine, New Orleans, LA 70112

Abstract: Patients (pts) with HIV-1 infection and immune suppression have an increased incidence of cancer. I have found that exogenously added p24 to resting peripheral blood mononuclear cells will suppress natural killer (NK) cell function. P24 is a circulating antigen in pts with HIV-1 infection. If p24 can bind to the surface of NK cells or other lymphocytes, it may provide another mechanism of cellular immune suppression that is not CD4 dependent. I have previously demonstrated the ability of the core protein, p24, to bind to activated killer cells (AK). NK-cell function as determined by the K562 cytolysis assay was depressed when exposed to p24, but corrected when activated with interleukin-2. The binding site for p24 on AK cells was demonstrated by DSS cross-linking techniques and 125I-labeled p24. The size of the p24 receptor is approx 50 kD. This site may be related to p24-mediated immune suppression independent of CD4 receptors. This additional mechanism of immune suppression may have a role in the increased susceptibility to cancer in pts with HIV-1 infection.
Keywords: Cell Line Cytotoxicity, Immunologic Gene Products, gag/*IMMUNOLOGY Human HIV Antigens/*IMMUNOLOGY HIV Infections/*IMMUNOLOGY Interleukin-2/*PHARMACOLOGY Killer Cells, Natural/*IMMUNOLOGY *Lymphocyte Transformation Lymphocytes/*IMMUNOLOGY Receptors, Virus/*IMMUNOLOGY Viral Core Proteins/*IMMUNOLOGY ABSTRACT

KWDcelllinecytotoxicity,immunologicgeneproducts,gag/KWDimmunologyhumanhivantigens/KWDimmunologyhivinfections/KWDimmunologyinterleukin-2/KWDpharmacologykillercells,natural/KWDimmunologyKWDlymphocytetransformationlymphocytes/KWDimmunologyreceptors,virus/KWDimmunologyviralcoreproteins/KWDimmunologyabstract
910830
M9181008

Copyright © 1991 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1991. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1991. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .